{"id":46265,"date":"2023-08-09T07:55:06","date_gmt":"2023-08-09T11:55:06","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/novavax-earnings-call-reveals-surprise-profit-but-stocks-still-slide\/"},"modified":"2023-08-09T07:55:08","modified_gmt":"2023-08-09T11:55:08","slug":"novavax-earnings-call-reveals-surprise-profit-but-stocks-still-slide","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=46265","title":{"rendered":"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide"},"content":{"rendered":"<div>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Key takeaways<\/h2>\n<ul>\n<li>Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall<\/li>\n<li>The biotech company downgraded its full-year revenue forecast<\/li>\n<li>Novava shares declined 3.8% on Tuesday and have lost 82% of their value in 12 months<\/li>\n<\/ul>\n<p>Can the pandemic hero companies find life after Covid? That\u2019s the main question investors are asking as the pharmaceuticals continue to convince on that front. Novavax was the latest to post earnings, which unveiled a surprise profit but not much to go on for revenue in the third quarter, as well as cutting its full-year guidance.<\/p>\n<p>It\u2019s not the only vaccine producer struggling to get by, but Novavax looked terminal earlier this year by its own admission. There are signs of life in the form of new cash flow and a South Korean company taking a stake in Novavax, but the shares closing down on Tuesday suggests Wall Street isn\u2019t yet sold on the company\u2019s long-term future.<\/p>\n<p><em>Are you noticing the varied performance of healthcare stocks in 2023? That&#8217;s your cue to focus on diversification. The <\/em><em data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/foundation-investment-kits?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\">Foundation Kits<\/em><em> by Q.ai are your answer, leveraging a nifty AI algorithm for data analysis and adjustments.<\/em><\/p>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p><em>Whether it&#8217;s tech or global trends, these themed Kits hold various assets, like stocks, precious metals, forex and bonds, crafted to help optimize your financial growth. It\u2019s investing without the hassle and with the potential for greater rewards.<\/em><\/p>\n<p><em data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/eJceLlVc6Bb\">Download Q.ai today<\/em><em> for access to AI-powered investment strategies.<\/em><\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">What did Novavax\u2019s earnings report look like?<\/h2>\n<p>We all enjoy a pleasant surprise, and Novavax\u2019s second-quarter earnings delivered on that front. The vaccine producer recorded a net income of $58 million for the quarter, translating to 58 cents per share. It\u2019s a sizable improvement from last year&#8217;s second quarter, which saw a $510.5 million net loss. Wall Street analysts had pegged a loss of $1.39 per share for Q2.<\/p>\n<p>Novavax\u2019s second-quarter sales reached $424.4 million, way up from the $185.9 million year-over-year figure. The forecast was for $239.2 million in revenue.<\/p>\n<p>Novavax is preparing to launch a new Covid vaccine in the fall, with Novavax CEO John Jacobs noting the company will see \u201clittle to no sales\u201d in the third quarter as the FDA won\u2019t decide whether to approve the new vaccine until September, with Novavax\u2019s revenue mainly relying on grants in the quarter.<\/p>\n<p>But the cracks in Novavax\u2019s armor are still there. The biotech company revised its full-year revenue forecast from $1.4-1.6 billion to $1.3-1.5 billion as it continues its restructuring plan to cut costs. Novavax intends to slash its 2024 R&amp;D and operating expenses by 40% to 50% compared to 2022.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Is anything else going on with Novavax?<\/h2>\n<p>It\u2019s been a turbulent year so far for the vaccine maker. In February, Novavax said there was \u201csubstantial doubt\u201d about its ability to continue trading throughout the year and that its 2023 revenues were \u201csubject to significant uncertainty\u201d. The company reported a full-year net loss of $658 million for 2022. In May, Novavax announced it was slashing 500 jobs across the business to save costs.<\/p>\n<p>There was a glimmer of hope in July when the Canadian government confirmed it would repay $350 million to Novavax or forfeited vaccine doses meant to be delivered, with the news sending Novavax shares surging 30%. The repayments likely played a large part in Novavax&#8217;s profit this quarter.<\/p>\n<p>Now it appears Novavax has a string of good fortune heading its way. SK Bioscience announced on Tuesday, coinciding with Novavax\u2019s earnings report, that it was buying a 7% stake in Novavax instead of payment owed from the vaccine maker. Novavax confirmed it was issuing 6.5 million shares to SK Bioscience for $84.5 million and renegotiated its debt to the South Korean pharmaceutical company to $154 million. It now owes SK Bioscience $65 million in cash.<\/p>\n<p>Talk about a rollercoaster.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Wall Street\u2019s reaction<\/h2>\n<p>As you can imagine, Novavax\u2019s share price has been through the wars. After reaching a high of $290 in February 2021, the stock steadily declined from the start of 2022 and is now worth just $7.23 after losing 82% of its value in the last 12 months.<\/p>\n<p>Unfortunately for Novavax, the earnings beat didn\u2019t help with clawing back some of those massive losses. Initially, the share price jumped to $8.46, but Wall Street focused on the fact Novavax has had to slash its full-year revenue forecast for 2023. The stock closed 3.8% down on Tuesday at $7.23.<\/p>\n<p>Tuesday was a bad day overall for the stock market due to Moody\u2019s downgrading 10 regional banks, warning bigger lenders could face the same situation. The S&amp;P 500 dipped 0.4%, the Dow Jones declined 0.45% and the Nasdaq fell nearly 0.8%.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">How is the pharma industry holding up in 2023?<\/h2>\n<p>Vaccine producers, after riding high on the pandemic profits, have struggled to find their way after the crisis was over &#8211; and that\u2019s reflected in the poor stock market performance in 2023.<\/p>\n<p>Moderna is in a similar position to Novavax; its revenue hopes are pinned on the upcoming fall vaccine to combat a particular strain of Covid. The company\u2019s share price closed at its lowest point in three years this week as the entire sector\u2019s share prices suffered as BioNTech\u2019s second quarter missed revenue expectations. Throughout 2023, Moderna shares have declined 44%, and BioNTech is down 31.5%.<\/p>\n<p>Pfizer, which partnered with BioNTech on the Covid vaccine and enjoyed record sales in the pandemic, has suffered a similar fall from grace. The pharmaceutical giant\u2019s share price has plunged 31% since the start of the year, with the company\u2019s valuation losing $144 billion since its 2021 peak.<\/p>\n<p>What do companies do when they\u2019re down but not out? Turn to M&amp;A. That\u2019s what\u2019s starting to happen in the sector: back in March, Pfizer agreed to acquire biotech cancer drug specialist Seagen for $43 billion to diversify away from the vaccine. In July, Biogen confirmed it was purchasing Reata Pharmaceuticals for $7.3 billion to add its pioneering new neuromuscular treatment to its line-up. We\u2019ve unlikely seen the end of deal announcements in this sector.<\/p>\n<p>At the other end of the spectrum, Eli Lilly and Novo Nordisk shares hit all-time highs as excitement mounts over weight loss drugs. Eli Lilly shares climbed 14.9% after a stellar earnings beat, while Novo Nordisk was up 17.2% at the news its obesity drugs also cut the risk of strokes and heart attacks.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">The bottom line<\/h2>\n<p>Novavax is just one example of many companies needing help finding a path forward. As all hopes lie on the FDA approval in September, that pivotal moment will send the stock soaring or plummeting depending on the outcome.<\/p>\n<p>The reality is Novavax\u2019s share price is far from the 2021 highs. With what looks like the worst of the pandemic behind us, pharmaceuticals will need to refocus their attention on new growth areas or risk dying out.<\/p>\n<p><em>Healthcare stocks are a real mixed bag in 2023, which is a reminder that diversification across your portfolio is key to a low-stress investment strategy. You can take it one step further with Qai\u2019s <\/em><em data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/foundation-investment-kits?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\">Foundation Kits<\/em><em>, which utilize an AI helper to handle the heavy lifting.<\/em><\/p>\n<p><em>Each Kit is themed on different topics, like tech and global trends, holding a package of diversified assets to help give you the most bang for your buck. The AI is the star of the show by sifting through data and switching up each Kit\u2019s makeup to help you build wealth without the fuss.<\/em><\/p>\n<p><em data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/gs88E6Tc6Bb\">Download Q.ai today<\/em><em> for access to AI-powered investment strategies.<\/em><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/qai\/2023\/08\/09\/novavax-earnings-call-reveals-surprise-profit-but-stocks-still-slide\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The biotech company downgraded its full-year revenue forecast Novava shares declined 3.8% on Tuesday and have lost 82% of their value in 12 months Can the pandemic hero companies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":46266,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-46265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=46265\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=46265\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-09T11:55:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-09T11:55:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/08\/1691582107_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=46265#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=46265\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide\",\"datePublished\":\"2023-08-09T11:55:06+00:00\",\"dateModified\":\"2023-08-09T11:55:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=46265\"},\"wordCount\":1260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=46265#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=46265\",\"url\":\"https:\/\/ifintechworld.com\/?p=46265\",\"name\":\"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-08-09T11:55:06+00:00\",\"dateModified\":\"2023-08-09T11:55:08+00:00\",\"description\":\"Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=46265#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=46265\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=46265#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide | iFintechWorld","description":"Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=46265","og_locale":"en_US","og_type":"article","og_title":"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide | iFintechWorld","og_description":"Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The","og_url":"https:\/\/ifintechworld.com\/?p=46265","og_site_name":"iFintechWorld","article_published_time":"2023-08-09T11:55:06+00:00","article_modified_time":"2023-08-09T11:55:08+00:00","og_image":[{"width":1200,"height":811,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/08\/1691582107_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=46265#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=46265"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide","datePublished":"2023-08-09T11:55:06+00:00","dateModified":"2023-08-09T11:55:08+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=46265"},"wordCount":1260,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=46265#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=46265","url":"https:\/\/ifintechworld.com\/?p=46265","name":"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-08-09T11:55:06+00:00","dateModified":"2023-08-09T11:55:08+00:00","description":"Key takeaways Novavax surprised on the upside with profit, but the company\u2019s hopes are pinned on FDA approval of its new Covid vaccine for this fall The","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=46265#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=46265"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=46265#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/46265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46265"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/46265\/revisions"}],"predecessor-version":[{"id":46267,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/46265\/revisions\/46267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/46266"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}